Clinical Trials in Tennessee

Showing 5321-5340 of 15,329 trials

A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop

NCT04175340

The objective of this study is to evaluate the safety and effectiveness of lubricating and rewetting drop (Test) compared to OPTI-FREE® Replenish® Rewetting Drops (Control) when used by habitual contact lens wearers to bilaterally lubricate and rewet soft (hydrophilic) contact lenses including silicone hydrogel contact lenses and gas permeable (silicone acrylate and fluoro silicone acrylate) contact lenses.

Contact Lens Wear

Bausch & Lomb Incorporated369 participantsStarted Nov 2019

San Francisco, California, United States • Torrance, California, United States • Sarasota, Florida, United States +12 more locations

TERMINATEDPhase 329 miles

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT04128696

The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC).This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 inducible T cell co-stimulatory receptor (ICOS) agonist and pembrolizumab to pembrolizumab plus placebo in participants with programmed death receptor 1-ligand 1 (PD-L1) combined positive score (CPS) \>=1 R/M HNSCC.

Neoplasms, Head and Neck

GlaxoSmithKline315 participantsStarted Nov 2019

Duarte, California, United States • Washington D.C., District of Columbia, United States • St. Petersburg, Florida, United States +160 more locations

A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Find Trials by Condition in Tennessee

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Belimumab Assessment of Safety in SLE

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Impact of Microvascular Inflammation on Kidney Allograft Outcome

Study of ASN004 in Patients With Advanced Solid Tumors

C-myc Biomarker Study for Diabetic Foot Ulcers

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Feasibility Study on LITT for Medical Refractory Epilepsy

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma